Pembrolizumab shows survival benefit for patients with renal cancer
For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the ...
Feb 1, 2024
0
1